Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
sitagliptin
NPH insulin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes, sitagliptin, NPH insulin, GLP-1
Eligibility Criteria
Inclusion Criteria
- outpatients with T2D inadequately controlled with metformin plus glyburide
- HbA1c levels between 6.6 and 10%
- body mass index < 35 kg/m2
Exclusion Criteria
- heart failure
- respiratory failure
- uncontrolled hypertension
- impaired hepatic function
- impaired reanl function
- endocrine disorder
- gastrointestinal disorder
- malignancy
- alcohol abuse
- previous use of insulin
- previou use of based incretin therapy
- type 1 diabetes.
Sites / Locations
- University of Sao Paulo General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
sitagliptin
NPH insulin
Arm Description
100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
Outcomes
Primary Outcome Measures
improvement in HbA1c levels
Changes in fasting blood levels of HBA1c (%)
Secondary Outcome Measures
improvement of beta cell function with a meal test
Changes in serum C-peptide levels (ng/mL)
improvement on alpha cell function with a meal test
Changes in plasma glucagon levels (pg/mL)
Full Information
NCT ID
NCT02607410
First Posted
November 6, 2015
Last Updated
November 17, 2015
Sponsor
University of Sao Paulo General Hospital
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo
1. Study Identification
Unique Protocol Identification Number
NCT02607410
Brief Title
Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D
Official Title
Short and Long Term Effects of a Dypeptidil-peptidase-4 Versus Bedtime NPH Insulin as add-on Therapy in Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
January 2012 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Sao Paulo General Hospital
Collaborators
Fundação de Amparo à Pesquisa do Estado de São Paulo
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To compare the short and long term effects of inhibitor of the DPP-IV enzyme, sitagliptin , with bedtime NPH insulin in patients with T2D inadequately controlled with sulphonylurea plus biguanide: effects on beta cell function and on metabolic profile.
Detailed Description
Glucose control is fundamental in the treatment of type 2 diabetes (DM2). Studies suggest that drugs that boost levels of glucagon-like peptide (GLP-1) improve glycemic control and have long-term beneficial effect on the function of pancreatic beta cells. Objective: To compare the short and long term effects of sitagliptin (which inhibits the DPP-IV enzyme, increasing the levels of GLP-1) with bedtime NPH insulin in patients with T2D inadequately controlled with sulphonylurea plus biguanide. Effects on beta cell function and on metabolic profile were analyzed. Methods: 40 patients with DM2, HbA1c between 6.6 to 10%, in use of metformin and glibenclamide will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group). Measurements of HbA1c, metabolic and hormonal profile at fasting and post-meal (every 30 minutes for 4 hours) will be evaluated before and after 6 months (short term) and 12 months (long term) of adding sitagliptin or NPH insulin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 diabetes, sitagliptin, NPH insulin, GLP-1
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
sitagliptin
Arm Type
Active Comparator
Arm Description
100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
Arm Title
NPH insulin
Arm Type
Active Comparator
Arm Description
NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
Intervention Type
Drug
Intervention Name(s)
sitagliptin
Other Intervention Name(s)
DPP-4 inhibitor
Intervention Description
patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
Intervention Type
Drug
Intervention Name(s)
NPH insulin
Other Intervention Name(s)
long-acting insulin
Intervention Description
patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
Primary Outcome Measure Information:
Title
improvement in HbA1c levels
Description
Changes in fasting blood levels of HBA1c (%)
Time Frame
six and twelve months
Secondary Outcome Measure Information:
Title
improvement of beta cell function with a meal test
Description
Changes in serum C-peptide levels (ng/mL)
Time Frame
six and twelve months after each therapy at times zero, 30, 60, 120 and 180 minutes after meal test
Title
improvement on alpha cell function with a meal test
Description
Changes in plasma glucagon levels (pg/mL)
Time Frame
six and twelve months after each therapy at times zero, 30, 60, 120 and 180 minutes after meal test
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
outpatients with T2D inadequately controlled with metformin plus glyburide
HbA1c levels between 6.6 and 10%
body mass index < 35 kg/m2
Exclusion Criteria
heart failure
respiratory failure
uncontrolled hypertension
impaired hepatic function
impaired reanl function
endocrine disorder
gastrointestinal disorder
malignancy
alcohol abuse
previous use of insulin
previou use of based incretin therapy
type 1 diabetes.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria ER Siva, MD, PhD
Organizational Affiliation
University of Sao Paulo General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Sao Paulo General Hospital
City
Sao Paulo
ZIP/Postal Code
05403-000
Country
Brazil
12. IPD Sharing Statement
Citations:
PubMed Identifier
22685234
Citation
Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, Chen Y, Alba M, Holst J, Ferrannini E. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 Aug;97(8):2818-26. doi: 10.1210/jc.2012-1205. Epub 2012 Jun 8.
Results Reference
background
PubMed Identifier
24296715
Citation
Aulinger BA, Bedorf A, Kutscherauer G, de Heer J, Holst JJ, Goke B, Schirra J. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes. 2014 Mar;63(3):1079-92. doi: 10.2337/db13-1455. Epub 2013 Dec 2.
Results Reference
background
PubMed Identifier
20920044
Citation
Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab. 2010 Oct;12(10):909-15. doi: 10.1111/j.1463-1326.2010.01254.x.
Results Reference
background
Learn more about this trial
Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D
We'll reach out to this number within 24 hrs